The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27.
about
Novel Molecular Markers for Breast CancerA phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.High cyclin E staining index in blastemal, stromal or epithelial cells is correlated with tumor aggressiveness in patients with nephroblastoma.ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell linesLow-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.siRNA-based targeting of cyclin E overexpression inhibits breast cancer cell growth and suppresses tumor development in breast cancer mouse model.Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer.Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplificationA novel interaction between HER2/neu and cyclin E in breast cancer.Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C.LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patientsToo much cleavage of cyclin E promotes breast tumorigenesis.Impact of cyclin E overexpression on Smad3 activity in breast cancer cell linesCdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin EBreast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune responseIndole-3-carbinol and its N-alkoxy derivatives preferentially target ERα-positive breast cancer cellsIL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells.AKAP95 promotes cell cycle progression via interactions with cyclin E and low molecular weight cyclin E.A jekyll and hyde role of cyclin E in the genotoxic stress response: switching from cell cycle control to apoptosis regulation.Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancerCyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells.Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast CancerAltered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation.Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells.Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progressionQuantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924.A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels.Post-translational modification and stability of low molecular weight cyclin E.In the wrong place at the wrong time: does cyclin mislocalization drive oncogenic transformation?Immunohistochemical expression of cell-cycle regulators in pediatric embryonal brain tumors.Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.Cyclin e expression and prognosis in breast cancer patients: a meta-analysis of published studies.
P2860
Q26753160-BB0CD0FD-2071-409F-BAC6-7BA92260069AQ33165699-E9639EFD-3AFD-4D71-BEB4-D9A83CD9F7B1Q33336382-15C07042-7DD7-4FC8-AFC9-5238EBB045A3Q33593873-00117C48-C214-43A5-ADB4-4192FBD6ECC6Q33658276-DF687412-1148-4615-A331-1B860FE9438DQ33705021-3870CAC7-25D5-4F71-AF52-035590F23525Q33920769-EBA4D27F-2ED0-4129-AF41-3A90B1606886Q33925994-8B68AED1-012A-4F42-8296-F04CCF47FA45Q33976264-13201B66-DF7F-4759-9718-65191961FCDDQ34157822-B71C9EB5-9158-44D2-8F36-D8D22BA8308AQ34220979-3683C458-17EA-4412-A561-1EC4815D92BDQ34221065-9813DD1C-14BF-46F4-9927-49A1029D2027Q34619813-AF72615E-0ADC-4143-8D09-D79C8680C659Q34901237-A729FDF4-29FC-49FB-8724-249B726519ABQ36096051-D95F06FC-3D1C-4AED-A626-EA412BAD92DFQ36187728-66309AA0-E43C-4CCD-82B1-B4264F657E35Q36288515-CCEBD9EA-5A56-4F0F-A4A6-670F6A3652EAQ36841253-2B2B7712-63BC-4A77-AE35-DA34906EE764Q36848850-A09CD68D-AF42-47CD-9C0C-69B676C42711Q36903296-96311C68-8340-4FE5-9C65-B93F41A2D530Q36918276-DE5F1B78-C1BB-4045-AA80-A437B1981A76Q37057171-967B3957-1555-45F8-A428-F9FD63FB5421Q37160444-BA2835B6-84A1-437B-83E7-D6D7A1A59F10Q37172133-81C3921E-0A99-425B-8A26-C770160B7493Q37215894-525A7AC4-CC52-4F6B-974A-9A94101CCF5FQ39451819-C48C28D6-7D60-4670-8893-00B18C057C1BQ39818985-AA0CA475-3756-41E5-8681-BB43AD700381Q39831876-597EE5C6-490E-4914-8392-5200612AE20BQ43429196-76D748E4-4714-4C18-9320-0C270A81035FQ48450978-2B8122DA-D20D-4B8D-A6EF-1AFB10D7E050Q49558301-68303EF6-DCE4-4BFD-AF08-72835670EF3AQ52955581-5E68C3B8-B84B-416E-8A0B-1792D9C31D05Q53598681-B56ED8DF-F99D-4613-B55C-79B94D4767F2
P2860
The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The tumor-specific hyperactive ...... to inhibition by p21 and p27.
@en
type
label
The tumor-specific hyperactive ...... to inhibition by p21 and p27.
@en
prefLabel
The tumor-specific hyperactive ...... to inhibition by p21 and p27.
@en
P2093
P2860
P356
P1476
The tumor-specific hyperactive ...... to inhibition by p21 and p27.
@en
P2093
Hannah Wingate
Isabelle Bedrosian
J Wade Harper
Khandan Keyomarsi
Mollianne J McGarhen
Ning Zhang
P2860
P304
15148-15157
P356
10.1074/JBC.M409789200
P407
P577
2005-02-10T00:00:00Z